Preeminent Neuropsychiatry Physician Joins Scientific Advisory Board of Alzheimer’s Disease R&D Company Division of Genocore Biotech.

Shenzhen, China -- (SBWire) -- 12/28/2015 --Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody, today announced that the company has appointed HonWen Long, M.D., to its Scientific Advisory Board. Dr. Wen Long is a preeminent researcher with expertise in device-based research for Neuropsychiatric Disorders. Currently Dr. Wen Long is Professor of Psychiatry, Neurology & Medicine.

"I am pleased to join the Scientific Advisory Board of Genocore Biotech. The Company's work, while early stage, offers a potentially new approach to the treatment of Alzheimer's disease, affecting million people in around the world. Alzheimer's is also the only top ten killer for which there are no effective treatment options available. " said Dr. Wen Long.

"Researchers across the world are racing towards a cure for Alzheimer's disease. But as prevalence rates climb, their focus has broadened from treatment to prevention strategies. What they've discovered is that it may be possible to prevent or delay the symptoms of Alzheimer's disease and other dementias through a combination of healthy habits.

Fears about Alzheimer's may discourage you from taking action. But by identifying and controlling your personal risk factors, you can maximize your chances of lifelong brain health and take effective steps to preserve your cognitive abilities." continued Dr. Wen Long.

"We are extremely pleased to welcome Dr. Wen Long to our Scientific Advisory Board," said Mr. Wang Yen Horng, president and CEO of Genocore Biotech. "Dr. Wen Long's expertise, experience and background will be invaluable as we navigate the path forward and try to develop a new and more effective treatment for Alzheimer's disease."

About Genocore-Biotech.com
Genocore-Biotech.com is an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs) and Fc-fusion protein drugs. With a total investment of about 95 million USD, about 110 employees and R&D lab, Process Development lab, Analytical & Quality center, and a cGMP clinical production facility the firm is a respectable player in the medical industry. Genocore Biotech has a highly experienced and well-integrated expert team whose expertise covers all the key steps of mAb drug research and development. They have on average 15-20 years of hand-on working experience at leading western biopharmaceutical companies.

For Media Contact:
Company: Genocore-Biotech.com
Address: Excellence Century Plaza
Tower 1, Fuhua 3rd Road, Futian District
Shenzhen, People's Republic of China
Tel: +86 755 330 595 45
Email: media@genocore-biotech.com